Efficacy of continuous glucose monitoring in comparison to self-blood glucose monitoring in patients with type 2 diabetes mellitus under insulin treatment: a systematic review and meta-analysis
Abstract
BACKGROUND: Diabetes Mellitus (DM) affects approximately 10.5% of the global population, necessitating effective glucose monitoring to mitigate complications. Self-monitored blood glucose (SMBG) lacks dynamic glycemic profiling, while continuous glucose monitoring (CGM) provides real-time/intermittent data. This review compares CGM and SMBG in insulin-treated type 2 diabetes (T2DM) patients. METHOD: A systematic review and meta-analysis of randomized controlled trials (RCTs) from PubMed, Web of Science, and Scopus was conducted until May 2025 and included RCTs compared CGM with SMBG in terms of glycemic indices in adults with T2DM on insulin therapy (± oral agents), excluding studies < 6 weeks or non-insulin treatments. Meta-analysis using a random-effect model was performed. RESULTS: Thirteen RCTs (n = 1550) were included. CGM significantly reduced HbA1c (mean difference [MD] = − 2.78 mmol/mol, 95% CI: −4.68 to − 0.88) and TBR (MD = − 1.30%, 95% CI: −1.94 to − 0.65) versus SMBG. TAR reduction (MD = − 4.12%, 95% CI: −9.11 to 0.88) and TIR increase (MD = 4.04%, 95% CI: −0.09 to 8.17) were non-significant. Substantial heterogeneity in HbA1c (I²=89.66%) persisted despite subgroup analyses based on CGM type. DISCUSSION: CGM improves long-term glucose control (HbA1c) and hypoglycemia risk (TBR) in insulin-treated T2DM, supporting its clinical utility. Non-significant TIR/TAR trends may reflect limited statistical power. Future studies are warranted to delineate the outcome…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 1,550 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.